Researchers discover a cell plasticity and inflammation driving druggable copper-signaling pathway

Inflammation is a protective body response to external noxious stimuli, enabling host defense and tissue repair mechanisms. However, excessive inflammatory response causes tissue injury and may lead to organ failure.

However, a scarcity of effective drugs to treat severe inflammation exists, thus, necessitating therapeutic innovations.

Study: Discovery of a druggable copper-signaling pathway that drives cell plasticity and inflammation. Image Credit: ALIOUI MA/Shutterstock
Study: Discovery of a druggable copper-signaling pathway that drives cell plasticity and inflammation. Image Credit: ALIOUI MA/Shutterstock

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Background

Macrophages are inflammatory mediators that mediate tissue repair and act as defense mechanisms against pathogens. Inflammatory macrophages show higher CD44 expression. CD44 is a cell surface marker that is efficacious in resolving lung inflammation; its deficiency can cause hyaluronic acid accumulation in the lungs.

Hyaluronic acid (HA) induces pro-inflammatory cytokine expression in alveolar macrophages. CD44, expressed in response to activated immune cells, acts as a metal transporter that promotes copper uptake.

The study

A study posted to the bioRxiv* preprint server identified mechanisms regulating immune cell plasticity to develop new therapeutics.

Here, CD44 mediated mitochondrial copper uptake and its consequences were studied and a drug targeting the mitochondrial copper was developed.

A copper-signaling pathway was discovered, which regulates macrophage plasticity towards an inflammatory state.

Findings

It was found that CD44, a pro-inflammatory cell surface marker, mediates copper uptake and enables macrophage activation.

A labile pool of copper(II) exists in the mitochondria of inflammatory cells, along with a specific chemical reaction. Oxidized nicotinamide adenine dinucleotide (NAD+) maintenance allows for epigenetic programming and triggers the expression of inflammatory genes. When macrophages are exposed to various pathogens, such as bacteria and viruses, this mechanism comes into effect.

Since inflammation is common to a spectrum of diseases as well as certain physiological processes, uncovering and targeting mechanisms underlying cell activation and plasticity are essential for designing novel therapeutic strategies.

CD44 regulates cell plasticity in specific cell types. Copper plays a crucial role in immune defense and protects against bacteria by promoting the generation of reactive oxygen species (ROS). The results of this study revealed that mitochondrial copper(II) levels escalate during macrophage activation—which can be targeted with small molecules.

In addition, the mitochondria of inflammatory macrophages harbor higher levels of hydrogen peroxide. Although this substrate was earlier deemed potentially toxic, the up-scaled production of hydrogen peroxide seems to be aimed at replenishing the pool of NAD+ from NADH. This mechanism may be more favorable than de novo biosynthesis, with respect to the energy requirement of the cells. Hence, hydrogen peroxide can serve as a functional metabolite.

A chemical reaction was described, in which copper(II) activates hydrogen peroxide; this enables the reduction of the metabolite via NADH to yield NAD+. It was proposed that complex I of the electron transport chain (ETC), harboring an NADH binding site, along with imidazole-containing histidine residues close to the flavin mononucleotide (FMN), aid in the reduction of hydrogen peroxide.

Identification of numerous iron-dependent demethylases and acetyltransferases signified a common epigenetic mechanism underlying macrophage activation.

Moreover, a copper-catalyzed reaction was found to be feasible without enzymatic action. Imidazole, which occurs in mitochondrial proteins, binds to copper(II) and can catalyze this reaction. However, when copper is scarce or absent, NADH and hydrogen peroxide yield by-products of oxidation. Therefore, copper(II) prevents NADH degradation and aids in maintaining NAD(H) redox cycling.

The same is true for the reactivity of enamines towards dimethyldioxirane—which produces highly reactive epoxides. Epoxide hydrolases are present in the mitochondria of mammalian cells.

Interestingly, epoxide hydrolases have been detected in the mitochondria of mammalian cells; these prevent the accumulation of chemically reactive species and hence ward off alkylation by-products. Imidazole residues in the mitochondria catalyze the reaction of copper(II) – thus, suggesting a probable enzyme-mediated process.

It was inferred that acute inflammation resembles metabolic disease and can be mitigated by modulating cell plasticity by targeting mitochondrial copper(II).

Metformin is known for its broad anti-inflammatory action and is now being tested for its anti-aging properties. A major drawback of this drug is low potency, thus, necessitating a high dosage. Other biguanide derivatives have shown better potency, for instance – LCC-12. These alternatives can render improvements and clinical and biological characterization of this class of drugs feasible.

Conclusion

The results illustrate how copper plays a central role in the regulation of cell plasticity and disclose a novel therapeutic strategy that employs modulation and refining of the epigenetic cell states.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • May 17 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Nidhi Saha

Written by

Nidhi Saha

I am a medical content writer and editor. My interests lie in public health awareness and medical communication. I have worked as a clinical dentist and as a consultant research writer in an Indian medical publishing house. It is my constant endeavor is to update knowledge on newer treatment modalities relating to various medical fields. I have also aided in proofreading and publication of manuscripts in accredited medical journals. I like to sketch, read and listen to music in my leisure time.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Saha, Nidhi. (2023, May 17). Researchers discover a cell plasticity and inflammation driving druggable copper-signaling pathway. News-Medical. Retrieved on November 22, 2024 from https://www.news-medical.net/news/20220331/Researchers-discover-a-cell-plasticity-and-inflammation-driving-druggable-copper-signaling-pathway.aspx.

  • MLA

    Saha, Nidhi. "Researchers discover a cell plasticity and inflammation driving druggable copper-signaling pathway". News-Medical. 22 November 2024. <https://www.news-medical.net/news/20220331/Researchers-discover-a-cell-plasticity-and-inflammation-driving-druggable-copper-signaling-pathway.aspx>.

  • Chicago

    Saha, Nidhi. "Researchers discover a cell plasticity and inflammation driving druggable copper-signaling pathway". News-Medical. https://www.news-medical.net/news/20220331/Researchers-discover-a-cell-plasticity-and-inflammation-driving-druggable-copper-signaling-pathway.aspx. (accessed November 22, 2024).

  • Harvard

    Saha, Nidhi. 2023. Researchers discover a cell plasticity and inflammation driving druggable copper-signaling pathway. News-Medical, viewed 22 November 2024, https://www.news-medical.net/news/20220331/Researchers-discover-a-cell-plasticity-and-inflammation-driving-druggable-copper-signaling-pathway.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Inequities in COVID-19 vaccination coverage for older adults highlighted in global study